Coquitlam, Canada

Shifeng Liu

USPTO Granted Patents = 30 

 

Average Co-Inventor Count = 9.6

ph-index = 13

Forward Citations = 339(Granted Patents)


Location History:

  • Port Coquitlam, CA (US) (2011)
  • Coquitlam, CA (2008 - 2016)
  • Burnaby, CA (2016)

Company Filing History:


Years Active: 2008-2016

Loading Chart...
Loading Chart...
30 patents (USPTO):Explore Patents

Title: Shifeng Liu: Innovator in Therapeutic Agents

Introduction: Shifeng Liu, based in Port Coquitlam, Canada, is a prolific inventor with an impressive portfolio of 30 patents. His work primarily focuses on developing novel therapeutic agents that target sodium channel-mediated diseases, contributing significantly to the pharmaceutical industry.

Latest Patents: Among his latest innovations are two noteworthy patents. The first is for "Biaryl ether sulfonamides and their use as therapeutic agents," which outlines biaryl ether sulfonamides, and pharmaceutically acceptable derivatives for treating or preventing sodium channel-mediated diseases, particularly pain. The second patent focuses on "Spiro-oxindole compounds and their use as therapeutic agents." This invention details spiro-oxindole compounds, including stereoisomers and their salts, aimed at the same therapeutic goals.

Career Highlights: Shifeng Liu has had an esteemed career, having worked with prominent companies such as Xenon Pharmaceuticals Inc. and Novartis AG. His contributions in these organizations have advanced the understanding and development of drug therapies targeting complex medical conditions.

Collaborations: Throughout his professional journey, Liu has collaborated with esteemed colleagues such as Shaoyi Sun and Rajender Kamboj. These partnerships have fostered a dynamic environment for innovation, leading to significant advancements in therapeutic research.

Conclusion: Shifeng Liu’s contributions to the field of pharmacology and therapeutic agent development are noteworthy. With a robust list of patents and meaningful collaborations, he continues to influence the landscape of medical treatments, particularly in addressing pain and sodium channel-related disorders.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…